PhRMA Willing To Contribute To Drug ‘Affordability’ – But Mum On How Much
Executive Summary
PhRMA CEO Steven Ubl offers list of policy alternatives to drug pricing bills pending in the US Congress that he argues would stifle innovation; industry's plans, on the other hand, could produce "meaningful" legislation.